Torin 1 is a tricyclic benzonaphthyridinone that inhibits mTORC1/2 and exhibits anti-inflammatory, anti-angiogenic, anti-metastatic, and anticancer chemotherapeutic activities. In macrophages, torin 1 decreases cytokine production and inflammatory response signaling. In colorectal cancer cells, this compound induces apoptosis and inhibits growth, motility, invasiveness, and survival; it also inhibits tumor growth and vessel formation in vivo.
| Cas No. | 1222998-36-8 |
|---|---|
| Purity | ≥98% |
| Formula | C35H28F3N5O2 |
| Formula Wt. | 607.64 |
| IUPAC Name | 1-[4-(4-Propionyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]-9-(3-quinolinyl)benzo[h][1,6]naphthyridin-2(1H)-one |
| Solubility | 1mM with gentle warming in DMSO |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Shappley RK, Spentzas T. Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA. Int J Inflam. 2014;2014:560790. PMID: 24800098.
Francipane MG, Lagasse E. Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget. 2013 Nov;4(11):1948-62. PMID: 24185040.
Liu Q, Chang JW, Wang J, et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55. PMID: 20860370.
